

Nashwa El-Gendy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10781341/publications.pdf>

Version: 2024-02-01

19
papers

491
citations

759233

12
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

668
citing authors

#	ARTICLE	IF	CITATIONS
1	Formulation and Characterization of Nanocluster Ceftazidime for the Treatment of Acute Pulmonary Melioidosis. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 3399-3408.	3.3	9
2	Antibiotic Activity of Iron-Sequestering Polymers. <i>Biomacromolecules</i> , 2015, 16, 1480-1488.	5.4	12
3	NanoCluster Itraconazole Formulations Provide a Potential Engineered Drug Particle Approach to Generate Effective Dry Powder Aerosols. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2015, 28, 341-352.	1.4	14
4	Pulmonary Delivery of Vancomycin Dry Powder Aerosol to Intubated Rabbits. <i>Molecular Pharmaceutics</i> , 2015, 12, 2665-2674.	4.6	16
5	NanoClusters Surface Area Allows Nanoparticle Dissolution with Microparticle Properties. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1787-1798.	3.3	12
6	NanoCluster budesonide formulations enable efficient drug delivery driven by mechanical ventilation. <i>International Journal of Pharmaceutics</i> , 2014, 462, 19-28.	5.2	14
7	Delivery and performance of surfactant replacement therapies to treat pulmonary disorders. <i>Therapeutic Delivery</i> , 2013, 4, 951-980.	2.2	23
8	Development of Budesonide Nanocluster Dry Powder Aerosols: Processing. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 3425-3433.	3.3	11
9	Development of Budesonide Nanocluster Dry Powder Aerosols: Formulation and Stability. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 3445-3455.	3.3	16
10	Development of Budesonide Nanocluster Dry Powder Aerosols: Preformulation. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 3434-3444.	3.3	10
11	Nanocluster Budesonide Formulations Enhance Drug Delivery through Endotracheal Tubes. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 1063-1072.	3.3	12
12	Particle Engineering Technologies for Pulmonary Drug Delivery. , 2011, , 283-312.		5
13	Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 522-533.	4.0	35
14	Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent. <i>International Journal of Pharmaceutics</i> , 2010, 391, 305-312.	5.2	28
15	Agglomerates of Ciprofloxacin Nanoparticles Yield Fine Dry Powder Aerosols. <i>Journal of Pharmaceutical Innovation</i> , 2010, 5, 79-87.	2.4	28
16	Iodinated NanoClusters as an Inhaled Computed Tomography Contrast Agent for Lung Visualization. <i>Molecular Pharmaceutics</i> , 2010, 7, 1274-1282.	4.6	32
17	Budesonide Nanoparticle Agglomerates as Dry Powder Aerosols With Rapid Dissolution. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 2731-2746.	3.3	76
18	Combination Chemotherapeutic Dry Powder Aerosols via Controlled Nanoparticle Agglomeration. <i>Pharmaceutical Research</i> , 2009, 26, 1752-1763.	3.5	73

#	ARTICLE	IF	CITATIONS
19	Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. International Journal of Pharmaceutics, 2009, 369, 136-143.	5.2	65